BranchLab Raises $26M for AI-Powered Pharma Commercialization

BranchLab, a trailblazer in applying artificial intelligence to pharmaceutical commercialization, has successfully closed a $26 million Series A funding round. The investment was spearheaded by McKesson Ventures, with significant contributions from FCA Venture Partners, Sanofi Ventures, and AIX Ventures. This infusion of capital propels the company's total funding to $35 million, signaling strong investor confidence in its innovative approach to bringing therapies to market.

The pharmaceutical industry has long grappled with inefficiencies in its commercialization processes, which typically involve patient identification, market segmentation, outreach, and performance tracking. These operations have historically been siloed, relying on disparate vendors and delayed data analysis, creating a bottleneck that hinders rapid adaptation and impact. BranchLab directly addresses this challenge by offering a unified, privacy-first AI platform designed to streamline these complex workflows.

By consolidating audience intelligence, activation strategies, and performance optimization into a single, accessible platform, BranchLab empowers pharmaceutical teams and their marketing partners. This enables near real-time engagement with high-intent patient and healthcare professional (HCP) groups. Early adoption by leading pharmaceutical firms has demonstrated remarkable results, with an average uplift of nearly 70% in commercialization effectiveness across various therapeutic areas. This significant improvement underscores the platform's ability to translate data into actionable strategies more efficiently.

“The pharmaceutical sector possesses vast amounts of data, but the critical hurdle has always been its swift and ethical utilization,” stated Josh Walsh, CEO of BranchLab. “Our solution transforms privacy-safe, aggregated data into immediate insights that directly inform activation efforts. This allows teams to accelerate their pace, target audiences with greater precision, and achieve superior outcomes without compromising sensitive or individual-level data.” The platform's proprietary transformer-based architecture is key, enabling models to train within secure, customer-controlled environments while deploying only anonymized demographic and media-related signals.

Investors highlighted the transformative potential of BranchLab's technology. Carrie Williams, partner at McKesson Ventures, noted the platform's capacity to redefine the patient journey by seamlessly integrating privacy-conscious targeting with patient access and support. Andrew Bouldin, Managing Partner at FCA Venture Partners, emphasized the fundamental shift BranchLab represents, moving beyond siloed data to real-time, integrated execution systems within regulated environments. Echoing this sentiment, Cris De Luca of Sanofi Ventures pointed to the broader industry trend towards embedded, responsible AI, positioning BranchLab as a foundational commercial intelligence layer for the future of pharmaceutical marketing.

The newly acquired funds will be instrumental in scaling BranchLab's enterprise deployments, enhancing integrations across the healthcare and media technology ecosystem, and further developing its comprehensive AI platform. As the healthcare industry increasingly prioritizes speed, accountability, and data privacy, BranchLab is strategically positioned to become an essential infrastructure provider for therapy commercialization in the AI-driven era.